We recently compiled a list of the 12 Stocks That Will Double in 2025. In this article, we are going to take a look at where ...

Axsome Therapeutics (NASDAQ:AXSM) has received FDA approval for its drug Symbravo for the acute treatment of migraine with or ...

Else Nutrition Holdings Inc (ELSE) reported a robust start to 2022 with significant revenue growth and improved profitability ...

According to a report by the Australian Bureau of Statistics (ABS) published on December 4, 2024, the Australian economy grew ...

Chimerix Inc (NASDAQ: NASDAQ:CMRX) stock has reached a new 52-week high, touching $4.22 in recent trading, giving the company a market capitalization of $375 million. According to InvestingPro data, ...

Clinical-stage biopharmaceutical company Tonix Pharmaceuticals (NASDAQ: TNXP) is gaining significant attention from investors and market participants. The company develops therapies for conditions ...

Verona Pharma (NASDAQ:VRNA)'s stock has reached an unprecedented peak, setting an all-time high at $56.49. This milestone underscores a remarkable period of growth for the $4.49 billion ...

Vir Biotechnology, Inc., a $1.5 billion market cap biotech company, announced a change in its executive team with the upcoming departure of Ann (Aine) M. Hanly, Ph.D., and the appointment of Maninder ...

Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.94 billion, finds itself at a critical juncture as it navigates challenges to its flagship Eylea franchise while ...

We run the ruler over ASX health stock quarterlies, with Bioxyne achieving record Q2 FY25 trading revenue. ... Read More The post ASX Quarterly Health Wrap: Bioxyne revenue up 77%, Radiopharm lists on ...

Several ASX-listed companies are undertaking phase III clinical trials, the critical final stage before potential regulatory ...

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB), a commercial-stage biopharmaceutical company with a "GOOD" InvestingPro Financial ...